Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

L-Asparaginase

L-Asparaginase Investigators have long sought to discover an exploitable metabolic lifference between the normal cell and the neoplastic cell. With this goal in nind, many compounds have been designed with exquisite biochemical easoning; however, when put through the acid test of a clinical trial, most of he effective agents have been incapable of discriminating to a significant legree between neoplastic and normal cells, especially those of the bone narrow and gastrointestinal tract. The current understanding of the :herapeutic effects of L-asparaginase represents the nearest approach to :uccess in this search. The development of L-asparaginase as a therapeutic agent began in _953 when Kidd (1, 2) reported that the growth of certain neoplasms in mice Lnd rats was inhibited by guinea pig serum but not by rabbit or horse sera. \t that time Kidd was investigating the possibility of immunotherapy for nurine lymphomas and was using guinea pig serum as a source of comple­ nent to enhance the antigen-antibody reaction with rabbit antilymphoma Lntisera. In the course of this work he observed that mice which received �uinea pig serum alone, experienced complete tumor regressions. At the :ime it was believed that an immunological phenomenon was operative iince the tumors were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Medicine Annual Reviews

Loading next page...
 
/lp/annual-reviews/l-asparaginase-szYX9E0HsA

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Annual Reviews
Copyright
Copyright 1970 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0066-4219
eISSN
1545-326X
DOI
10.1146/annurev.me.21.020170.002245
pmid
4913953
Publisher site
See Article on Publisher Site

Abstract

Investigators have long sought to discover an exploitable metabolic lifference between the normal cell and the neoplastic cell. With this goal in nind, many compounds have been designed with exquisite biochemical easoning; however, when put through the acid test of a clinical trial, most of he effective agents have been incapable of discriminating to a significant legree between neoplastic and normal cells, especially those of the bone narrow and gastrointestinal tract. The current understanding of the :herapeutic effects of L-asparaginase represents the nearest approach to :uccess in this search. The development of L-asparaginase as a therapeutic agent began in _953 when Kidd (1, 2) reported that the growth of certain neoplasms in mice Lnd rats was inhibited by guinea pig serum but not by rabbit or horse sera. \t that time Kidd was investigating the possibility of immunotherapy for nurine lymphomas and was using guinea pig serum as a source of comple­ nent to enhance the antigen-antibody reaction with rabbit antilymphoma Lntisera. In the course of this work he observed that mice which received �uinea pig serum alone, experienced complete tumor regressions. At the :ime it was believed that an immunological phenomenon was operative iince the tumors were

Journal

Annual Review of MedicineAnnual Reviews

Published: Feb 1, 1970

There are no references for this article.